Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Pipeline Review, H2 2017

  • ID: 4446934
  • Report
  • 38 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CanBas Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Globavir Biosciences Inc
  • NewLink Genetics Corp
  • Pfizer Inc
  • MORE
Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Pipeline Review, H2 2017

Summary

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Tryptophan 2, 3-dioxygenase is an enzyme that plays a critical role in tryptophan metabolism by catalyzing the first and rate-limiting step of the kynurenine pathway. It has specificity towards tryptamine and derivatives including D- and L-tryptophan, 5-hydroxytryptophan and serotonin.

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 8 and 3 respectively. Report covers products from therapy areas Oncology and Central Nervous System which include indications Glioblastoma Multiforme (GBM), Melanoma, Bladder Cancer, Liver Cancer, Parkinson's Disease and Solid Tumor.

The latest report Tryptophan 2,3 Dioxygenase - Pipeline Review, H2 2017, outlays comprehensive information on the Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)
  • The report reviews Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CanBas Co Ltd
  • F. Hoffmann-La Roche Ltd
  • Globavir Biosciences Inc
  • NewLink Genetics Corp
  • Pfizer Inc
  • MORE
Introduction

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Overview

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Companies Involved in Therapeutics Development

CanBas Co Ltd

Ensemble Therapeutics Corp

F. Hoffmann-La Roche Ltd

Globavir Biosciences Inc

Jiangsu Hengrui Medicine Co Ltd

Netherlands Translational Research Center BV

NewLink Genetics Corp

Pfizer Inc

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Drug Profiles

DN-1406131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBV-1012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBV-1073 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTI-1090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit IDO and TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-70099 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TDO-2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TDO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TDO for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Dormant Products

Tryptophan 2,3 Dioxygenase (Tryptamin 2,3 Dioxygenase or Tryptophan Oxygenase or Tryptophan Pyrrolase or Tryptophanase or TDO2 or EC 1.13.11.11) - Product Development Milestones

Featured News & Press Releases

Feb 10, 2015: IOmet Pharma demonstrates superior in vivo PK/PD properties in pre-clinical IDO, TDO and Dual IDO/TDO cancer immunotherapy programs

Feb 06, 2015: IOmet Pharma to present data on pre-clinical cancer immunotherapy programs at Keystone Tumor Immunology Symposium

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indication, H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by CanBas Co Ltd, H2

Pipeline by Ensemble Therapeutics Corp, H2

Pipeline by F. Hoffmann-La Roche Ltd, H2

Pipeline by Globavir Biosciences Inc, H2

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2

Pipeline by Netherlands Translational Research Center BV, H2

Pipeline by NewLink Genetics Corp, H2

Pipeline by Pfizer Inc, H2

Dormant Projects, H2

List of Figures

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indications, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CanBas Co Ltd
  • Ensemble Therapeutics Corp
  • F. Hoffmann-La Roche Ltd
  • Globavir Biosciences Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Netherlands Translational Research Center BV
  • NewLink Genetics Corp
  • Pfizer Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll